Exclusive Summary

• As the world's first approved targeted therapy for NASH/MASH without direct competition, it targets a massive untapped market of over 115 million patients globally.
• The planned 2027 US FDA (ANDA) filing demonstrates the supplier's top-tier cGMP quality system and high-barrier formulation R&D capabilities.
• With no generics currently approved globally, securing early distribution rights grants overseas partners a first-mover advantage for first-generic/early-launch opportunities.
• Compared to the innovator's ~$47,000 annual treatment cost, this high-quality generic offers significant price elasticity to rapidly penetrate global insurance and out-of-pocket markets.